Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cancer > Targeted Cancer Therapy > Flashcards

Targeted Cancer Therapy Flashcards

1
Q

What are targeted cancer therapies

A

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules involved in tumour growth and progression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the ways in which targeted chemotherapies can be given

A

oral therapies

- can be used in combination which surgery/conventional chemotherapy and radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

In what settings is targeted therapy used

A
  • Increasingly at earlier stages – slow down growth and prevent disease
  • Adjuvant setting (combination with other drugs)
  • Metastatic setting – relieve symptoms
  • Can be used in palliative setting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the two major growth pathway

A
  • PI3K

- MAPkinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what happens if you are able to block the major growth pathways

A
  • if we can block the Map Kinase pathway or the PI3 kinase pathway then this can block the growth that is seen in cancer cells where these pathways go into overdrive due to a mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the best target and the next best target that can be sued in cancer treamtent

A

• Best therapeutic targets are found in cancer cells but not in normal cells
• Next best targets – more targets in cancer cells than normal cells (e.g. gene amplification - overexpression of HER2 or EGFR) – this is where a oncogene is overexpressed
- then a drug that targets both cancer and normal cells and allowing the normal cell regenerates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the benefits of being able to find a specific target in order to treat the cancer

A
  • Reducing serious side effects – if you are specifically targeting a kinase then you are going to reduce targeted effects and side effects of cancer, the more specific the drug the fewer side effects that there is
  • Reducing use ineffective drugs
  • Improving patient survival
  • Improving quality of life
  • Reduce costs – drugs for a specific mutation that can be treated with a specific set of drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can you find targets for cancer treatment

A
  • Targets need to be sequenced by:
  • molecular biology,
  • genomics
  • bioformatics (is it an oncogenic change or an SNP change)
  • then this information is incorporated into the individualised patient treatment plan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where can the targets for cancer treatment mean

A
  • Can be at the growth factor
  • Extracellular side and intracellular side of the receptor
  • Within the nuclei
  • Growth factor receptor
  • Cytoplasm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the anatomy fo the tyrosine kinase receptor

A
  • transmembrane
  • has an extracellular domain and an intracellular domain
  • dimerises
  • intracellular domain is activated by phosphorylation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe how tyrosine kinase receptor carries out signalling

A
  • Binding of the ligand to the extracellular domain
  • this allows dimerisation of tyrosine kinases
  • dimerisation causes a conformational change in the intracellular domain meaning that the intracellular domain undergoes phosphorylation
  • once the tyrosine is phosphorylated they can then recruit adaptor proteins
  • this triggers a cascade of signalling proteins such as activation of MAPK and PI3K
  • this leads to increased growth and survival and motility of these cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Wha tis the MAPK pathway important for

A

Cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the PI3K pathway important for

A
  • cell growth
  • proliferation
  • agniogensis
  • metabolism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the common targets for the extracellular domain

A
  • EGFR
  • HER2/3/4
  • VEGFR
  • PDGFR
  • cKIT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the common targets for the tyrosine kinase domain

A
  • EGFR
  • HER2/3/4
  • VEGFR
  • PDGFR
  • cKIT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the common targets for the PI3K pathway

A

mTOR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

name some common targets in the tyrosine kinase receptor activation

A
  • extracellular domain of the tyrosine kinase receptor
  • tyrosine kinase domain
  • PI3K pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How can you block the tyrosine kinase receptor

A

block ATP from binding

- therefore phosphate is not able to phosphorylate the tyrosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is perhaps one of the most important oncogenic driver of human cancers

A

MAP Kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What does Cetuximab do

A

– binds to the Epidermal growth factor receptor and inhibit binding so we don’t get activation of the growth pathways
- inhibit dimerisation and therefore inhibit activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is cetuximab used to treat

A

2017 NICE recommended (EGFR)-expressing, RAS wild-type metastatic colorectal cancer/ recurrent or metastatic squamous cell cancer of the head and neck

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the two things that antibodies can do in antibody therapy (biological therapy)

A

• Antibody inhibitors of growth receptors.
o Bind to growth factor receptor and prevent growth signal.
• Antibody drug conjugates
o Antibody targets drug to tumour cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what drug targets VEGF

A
  • Bevacizumab (Avastin) VEGF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What drug targets HER2

A
  • Trastuzumab- (Herceptin) HER2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe how to name monoclonal antibodies

A
  •   -u- human (100% human antibody): Panitumumab
  •   -zu- humanized (95% human and 5% mouse): Trastuzumab (Herceptin ®)
  •   -xi- chimeric (65% human and 35% mouse): Rituximab (MabThera ®)
  •   -o- mouse, -a- rat, -e- hamster, -i- primate: Tositumomab

•  Previous syllable
–  -tu(m )- for tumour in general
– -ma(r)- breast, -pr(o)- prostate, - co(l)- colon, etc.
–  -ci(r)- for circulatory: Bevacizumab (Avastin ®)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What drug targets HER2/HER3

A

Pertuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

name the 5 drugs that antagonize ligand receptor signalling and inhibit dimerisation and ligand binding

A

EGFR

  • cetuximab
  • Panitumumab

HER2
- Trastuzumab

HER2/3
- Pertuzumab

VEGFR
- Bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Why is HER2 so oncogenci

A

HER2 does not bind to a ligand or to a growth factor so when the growth factor binds these receptors but you a dimerization arm so that two receptors can interact and bind to each other but HER2 is different, it has no ligand and doenst bind to a growth factor and the normal conformation of HER2 is the dimerization with the dimersiation arm, therefore all you need is an amplification of HER2 in the breast epithelial cells is a amplication for cancer
Therefore this is why HER2 is so oncogenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the 3 ways in which monoclonal antibodies works

A
  1. Kill tumour cell directly
  2. Killing tumour cells via an immune mediated mechanism
  3. Vascular or stromal ablation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Describe the ways in which the monoclonal antibodies work

A 
Killing tumour cell directly 
•	Inhibit ligand binding
•	Signalling blocked
•	Apoptosis induced
•	Possible delivery of 
     toxic payload

Killing tumour cells via an immune mediated mechanism
• Induction of phagocytosis
• Complement dependent cytotoxicity (CDC)
• Antibody dependent cell
cytotoxicity (ADCC)

Vascular or stromal ablation
- VEGF antagonism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Describe HER2 cancers

A
  • Approximately 15% breast cancers overexpress HER2.
  • Approximately 20% of these women respond to Herceptin (Trastuzumab)
  • Most women have disease progression within one year.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is recommended for HER2 breast cancer that is metastatic and recurrent

A
  • Pertuzumab, in combination with trastuzumab and docetaxel ( anti mitotic drug – stabilises microtubules and prevents them from breaking down - can’t carry out there normal function in mitosis therefore mitosis cannot occur), is recommended HER2 positive metastatic or locally recurrent unresectable (cannot have surgery) breast cancer
33
Q

How does Trastuzumab (Herceptin) work

A

Binds to domain IV on HER2

Supresses ligand-independent HER2 signalling – HER2 does not bind to the ligand, prevents two HER2 molecules interacting with each other therefore prevents homodimerization

Prevents HER2 ECD shedding

Identifies cells for antibody-dependent cell mediated cytotoxicity

Activate Endocytosis of the HER2 Receptors.

Inhibits Dimerization
Oncogenic because it has a dimerization arm.

Prevents Cleavage
o Prevents cleavage of HER2 receptor.
o If HER2 overexpressed: mutations.
o Allows extracellular part to be cleaved off.
o This causes for it to be continuously activated

34
Q

What is another word for Trastuzumab

A

Herceptin

35
Q

How does bevacizumab work

A

o Block the receptor.

o Inhibits tumour growth and metastasis.

36
Q

How does pertuzumab work

A

Binds to domain II on HER2 and Her1, 3 and 4 – therefore it inhibits ligand dependent HER2 signalling as it binds to HER1, HER3 and HER4 combination with HER2 therefore inhibits hertrodimiersation

Inhibits homo- and heterodimerisation

Supresses ligand dependent HER2 signalling Identifies cells for antibody-dependent cell mediated cytotoxicity

37
Q

What is the difference between Pertuzumab and Trastuzumab

A

Trastuzumab
- prevents homodimerisation

Pertuzumab
- inhibits homodimerisation and herterodimerization

38
Q

what does an monoclonal antibody that targets VEGFR do

A

prevents angiogenesis

39
Q

What is VEGF required for

A

o Required for the formation of new blood vessels.

40
Q

How does VEGF protect the endothelial cells from death

A

Protects endothelial cells from death via activation of PKC pathways and up-regulation of anti-apoptotic proteins such as Bcl-2

41
Q

what is the activity of VEGF mediated by

A
  • – Activity mediated by tyrosine kinase receptors, VEGFR 1 and VEGFR 2
42
Q

What does VEGF function indirectly as

A

a survival factor for tumour cells

43
Q

What inhibits VEGF function

A

Bevacizumab (Avastin)
o Block the receptor.
o Inhibits tumour growth and metastasis.
- deprives tumours of nutrient providing blood vessels

44
Q

What is bevacizumab approved for

A
  • Recurrent or metastatic cervical cancer,
  • Third line treatment of low grade gliomas (children)
  • First line treatment of advanced epithelial ovarian,
  • funded by the cancer drugs fund
45
Q

How do antibodies access tumour cells

A

Normal Tissue
• Blood vessels have intact endothelial layer.

Tumour Tissue
• Blood vessels leaky, so small and large molecules have access to malignant tissue.
• Tumour tissue: does not have a lymphatic drainage system.
o Macromolecules are retained.

There is an enhanced vascular permeability of circulating antibodies for tumour tissue and subsequent accumulation in solid tumours.

46
Q

What is a conjugated antibody

A
  • Cytotoxic drug can be attached via stable linked to Fc part.
  • When antibody binds to cancer cell: cytotoxic load will be adjacent
47
Q

Name an example of a conjugated antibody

A

Trastuzumab Emtansine (Kadcycla)

48
Q

Who is Trastuzumab Emtansine (Kadcycla) for

A
  • For women who are HER2+ but have inoperable breast cancer or metastatic breast cancer
  • Effective but expensive
49
Q

How much does Trastuzumab Emtansine (Kadcycla) improve lifespan by

A

5.8 months on average

50
Q

How do naked antibodies work

A
  1. activating the immune system such as Alemtuzumab - CLL
  2. targeting immune system checkpoints e.g. - PD-1 Keytruda - unresectabel advanced melanoma
  3. inhibiting the activity of the antigen and preventing growth such as herceptin - breast cancer
51
Q

How do antibody drug conjugates (ADC) work

A
  1. radiolabelled such as ibritumomab

2. chemolabelled such as traastuzumab emtansine - anti HER2 antibody conjugated to a chemotherapy drug called DM1

52
Q

What do tyrosine kinase inhibitors do

A
  • these work by blocking the kinase activity
53
Q

What are the types of tyrosine kinase inhibitors

A

Tyrosine Kinase Inhibitors of Growth Factors
• Bind to growth factor receptor and prevent growth signal.

Inhibition of other kinases - such as B-Raf and inhibitors in the MTOR and PI3K pathway

54
Q

what part of the tyrosine kinase receptor part can drugs be designed to inhibit

A
  • can be designed to sterically inhibit ATP binding
  • kinase domain has a binding pocket for ATP which causes phosphorylation so if this pocket is blocked then phosphorylation does not occur
55
Q

What is an example of a tyrosine kinase inhibitor that can inhibit the ATP binding domain preventing phosphorylation and what cancer is it used for

A
  • Tarceva (erlotinib) prevents ATP from binding = NICE -Used for locally advanced or metastatic NSCLC - EGFR
56
Q

What do small molecular tyrosine kinase inhibitors do and what is the advantage and disadvantage of them

A
  • these target the oncogene product
  • they inhibit signalling at key stages

Advantage

  • safer than chemotherapy
  • specific side effects and specificity is often relative
57
Q

What is the nomenclature of tyrosine kinase inhibitors

A

ib – inhibitory
tinib – tyrosine kinase inhibitors
e.g. gefitinib (Iressa) and erlotinib (Tarceva) (NSCLC)
imatinib (Glivec) (CML)

58
Q

What two types of cancer make up non small cell lung cancer

A

adenocarcinoma

squamous cell carcinoma

59
Q

What is the largest cause of non small cell lung cancer

A

adenocarcinoma

60
Q

What are the mutations that cause squamous cell non small cell lung cancer

A
  • Squamous cell cancer – mutations found – amplification of PI3CA and mutations in PI3CA
61
Q

What are the mutations found in adenocarcinoma non small cell lung cancer

A

mutations are in K-Ras, EGFR mutation,

62
Q

What is another name for HER2

A

ERBB2

63
Q

What are the activating mutations in tyrosine kinase domain of EGFR in lung cancer

A
  • there are mutations in exon 18, 19, 21 which occur in 50% of non small cell . lung cancer
  • Exon 19 and 21 are particularly important in causing activating mutations (change in ATP sites)
64
Q

What does a mutation at Exon 19 cause in non small cell lung cancer

A
  • increase in autophopsphorylation
  • cell survival via AKT increases
  • dimerisation increases
65
Q

What does a mutation at Exon 21 cause in non small cell lung cancer

A

dimerisation increases

66
Q

In non small cell lung cancer what are the activating mutations associated with

A
  • they are associated with drug sensitivity to gefitinib or erlotinib
67
Q

can drug resistance develop to targeted therapy

A

yes

68
Q

How does drug resistance develop to targeted therapy and give examples

A
  • cancerous cells carry on mutating
  • Mutations in tyrosine kinase domain of EGFR associated with drug resistance (TKI)- lung cancer
  • Up to 70 % these women do not respond or develop resistance to trastuzumab e.g. truncated HER2= breast cancer = one of the things that happen to HER2 is that there is a mutation with the extracellular domain that allows the site for protease to come along and cut of the top of the receptor, so if the receptor is truncated Trastuzumab ca no longer bind as the binding site is gone
69
Q

What is the most developed acquired resistance to

A
  • TKI - EGFR over-expression leading to a melanoma
70
Q

What are the mutations associated with drug resistance in tyrosine kinase domain of EGFR in lung cancer

A
  • Mainly on Exon 20
  • this mtuation is associated with resistance to gefitinib and erlotinib and prevents it from binding in the ATP binding site
71
Q

name the

  • first generation EGFR tyrosine kinase inhibitors
  • second generation EGFR tyrosine kinase inhibitors
  • third generation EGFR tyrosine kinase inhibitors
A

first (reversible)

  • Erlotinib
  • Gefitinib

Second (irreversible)
- Afatinib

Third (mutant selective - selective to the second mutation that occurs in lung cancer)
- Osimertinib (on the cancer drug fund)

72
Q

What are the side effects of targeted therapies

A 
Skin changes
Skin rashes (acneiform) – EGFR
Dry skin
Itchy skin
Hand foot syndrome - VEGF (peripheral neuropathy-small blood vessels)

Changes in hair (alopecia, brittle, may grow faster)

Dry or red eyes and red and tender eyelids

73
Q

What cancer drug can lead to high blood pressure

A

High blood pressure – VEGF

74
Q

What cancer drug can lead to slow wound healing and blood clotting

A

Slow wound healing and blood clotting – EGFR

75
Q

What cancer drug can lead to congestive heart failure

A

Congestive heart failure - HER2 - trastuzamab causes cardiotoxicity

76
Q

How does trastuzamab cause cardiotoxicity

A
  • HER2 is important in the survival pathway of cardiomyocytes
  • they also increase nitric oxide production which causes vasodilation which increases blood flow through the pulmonary arteries
  • if this is inhibited this can lead to a decrease in NO and endothelial cell dysfunction
77
Q

How often do you have to assess cardiac function with someone who is on trastuzumab

A
  • have to assess cardiac function before starting treatment
  • then test every 3 months
  • 7-28% of patients have side effects
  • and patients who have a left ventricular ejection fraction of less than 55% they are not prescribed trastuzumab and if this is reduced to less than 50% in treatment then it is stopped
78
Q

What are the effects of trasutzamab on the heart

A
  • Inhibition of HER2 survival pathway - this contributes to myocardial dysfunction

Congestive heart failure

  • reduces contracitle efficiency
  • leads to apoptosis of cardiomyocytes this indirectly increases myocardial workload
  • decline in left ventricular cardiac function

Endothelial dysfunction

  • injures epithelial cells by increasing the amount of reactive oxygen species
  • impaired vasodilation
  • decreases NO
  • reduces myocardial blood flow
79
Q

What combination of drugs is associated with HER2 life length increase

A

The combination of docetaxel, pertuzumab and trastuzumab is associated with a survival of more than 4.5 years, compared with a life expectancy of 1.5 years achieved 19 years ago in patients with metastatic HER2-positive breast cancer.

Cancer (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions